Key Highlights
- Senti Biosciences Holdings is indicated 10.41% lower at USD 0.0869 against a calculated prior close of USD 0.0970, following a USD 4.55 million Equity commitment disclosed on November 9, 2026.
- Bone Biologics holds USD 6.1 million in cash, which management expects to carry operations through the second quarter of 2027 against roughly USD 6 million of estimated yearly operating costs.
- The Connect Biopharma cash line, covering cash, equivalents and short-term investments, fell to USD 19.5 million by September 30, 2026 from USD 44.3 million, while the third quarter net loss reached USD 16.2 million.
- Shares outstanding for GRI Bio expanded by 339%, reaching roughly 2.19 million at September 30, 2026 versus 497,693 at December 31, 2025, after about 1.69 million at-the-market shares generated USD 8.2 million gross.
Senti Biosciences Holdings (NASDAQ:SNTI) Falls 10.41% to USD 0.0869 as an Equity Commitment Weighs
Shares of Senti Biosciences Holdings were priced at USD 0.0869 ahead of the November 18, 2026 session, marking a 10.41% retreat. Measured against a calculated prior close of USD 0.0970, the USD drop is minus USD 0.0101, and nothing dated that day explained the weakness. Back on November 9, 2026, the company arranged to sell as much as USD 4.55 million of its stock to CPIF II-9, an affiliate of Celadon Partners SPV 24, at the Nasdaq Minimum Price, a sum intended to keep operations running into late 2027. Payments under that arrangement arrive in five parts: USD 1.8 million on December 31, 2026, then USD 1.35 million on March 31, 2027, followed by two USD 500,000 instalments due June 30 and September 30, 2027, and a final USD 400,000 on December 31, 2027, which Senti Biosciences Holdings would receive in stages. By calculation, the first payment makes up 39.56% of the overall amount. At the indicated price the full commitment converts into roughly 52.36 million shares, with the first Tranche covering about 20.71 million of them for Senti Biosciences Holdings. Against the USD 1.00 Nasdaq minimum bid, the indicated figure for Senti Biosciences Holdings sits a calculated 91.31% lower, yet no deficiency notice surfaced, and figures for cash, debt, Revenue and net loss were absent.
Bone Biologics (NASDAQ:BBLG) Slides 9.44% to USD 0.2801 as a Bid Deadline Looms
Ahead of the November 18, 2026 session, Bone Biologics was priced at USD 0.2801, a drop of 9.44%. The earlier close is calculated at USD 0.3093, which means the USD move comes to minus USD 0.0292. That price represents 28.01% of the USD 1.00 minimum bid, leaving a calculated gap of USD 0.7199 per share. No catalyst linked to today's move was found, and the Business behind Bone Biologics reports no revenue, with a NELL-1/DBM spinal fusion pilot under way in Australia and FDA agreement on the study design for possible U.S. pivotal trials. Cash of USD 6.1 million set against estimated annual operating costs near USD 6 million works out to a calculated 1.02 times yearly spending. Management anticipates funding into the second quarter of 2027, but going-concern doubt remains. On the bid issue, Nasdaq delivered a deficiency notice to Bone Biologics, setting a 180-day window that ends March 9, 2027, a calculated 111 days from today, while earlier reverse splits failed to keep the stock above USD 1.00. The July 2026 private placement, meanwhile, bars variable rate deals and at-the-market sales until July 2027 without purchaser consent, narrowing the financing paths for Bone Biologics.
Connect Biopharma (NASDAQ:CNTB) Trades 9.05% Lower at USD 0.5264 Following Third Quarter Results
Connect Biopharma Holdings was indicated at USD 0.5264 in pre-market dealings on Wednesday, November 18, 2026, which is 9.05% lower. Against a calculated prior close of USD 0.5788, the decline equals minus USD 0.0524 a share. A calculated Market Capitalisation near USD 33.15 million emerges from 62.974 million weighted-average third quarter shares, far below USD 100 million, so small-cap Liquidity cautions apply. Third quarter numbers were released on November 16, 2026, and Connect Biopharma has no separate same-day catalyst on record. Cash, cash equivalents and short-term investments stood at USD 19.5 million, down from USD 44.3 million at year-end 2025, with total Assets of USD 27.8 million and equity of USD 12.1 million on the Balance Sheet of Connect Biopharma. The third quarter loss of USD 16.2 million, or USD 0.26 per share, narrowed from USD 17.2 million a year earlier, yet the nine-month Deficit deepened to USD 52.8 million against USD 40.4 million. Research spending came to USD 12.8 million, general and administrative outlays dropped to USD 4.3 million from USD 6.6 million, and going-concern language together with Nasdaq listing compliance head the risk list for Connect Biopharma Holdings, with further raises and dilution still possible.
GRI Bio (NASDAQ:GRI) Lower by 8.17%, Priced at USD 1.24, With Nothing New From Its Quarterly Update
GRI Bio is indicated at USD 1.24 on November 18, 2026, which translates into a pre-market slide of minus 8.17%. Dividing USD 1.24 by 0.9183 gives the calculated prior close of USD 1.35, and the calculated USD change is minus USD 0.11. Multiplying the roughly 2.19 million shares outstanding by the early price suggests a calculated Market Value of about USD 2.72 million, which places GRI Bio in nano-cap territory where swings are sharp. Nothing dated November 18, 2026 surfaced in coverage, while cash of USD 9.5 million at September 30, 2026 compared with a nine-month operating outflow of USD 6.6 million, and planned preliminary operations are expected to run into the second quarter of 2027. The company itself acknowledges doubt about continuing as a going concern. Its share count went from 497,693 to about 2.19 million, with around 517,000 warrants in issue, roughly 24% of the September 30 total, adding to dilution pressure at GRI Bio. According to the company, listed-securities market value sits below USD 5 million, and a Nasdaq listing rule now under review could bring suspension and delisting steps if it becomes effective. Anyone monitoring GRI Bio should follow how that review plays out.
Where Things Stand
Each of the four biotech names is trading lower before the open on November 18, 2026, and no confirmed catalyst on the same day has been identified. Senti Biosciences Holdings leads the group at a 10.41% fall, and its USD 4.55 million equity commitment raises dilution questions. Bone Biologics, with USD 6.1 million in cash, is lower by 9.44%. Connect Biopharma Holdings is down 9.05% against a calculated market capitalisation near USD 33.15 million, and GRI Bio has dropped 8.17%, and its calculated market value sits near USD 2.72 million. Across the group, going-concern wording and listing requirements keep surfacing, and this article is general information rather than Investment advice.


_11_20_2026_20_27_34_097200.jpg)



Please wait processing your request...